|
Test Patient #1
|
ID: | 111111 |
Name: | Test Patient #1 |
Gender: | F |
Client ID: | 11111 |
Age: | 19 |
Privacy Notice:
This document contains proprietary and confidential material
which is legally privileged. The contents of this document
may not be disclosed or distributed without the consent of
Premier Heart, LLC, or of the patient whose records are
contained herein.
|
| Test Patient #2 |
ID: | 222222 |
Name: | Test Patient #2 |
Gender: | M |
Client ID: | 22222 |
Age: | 97 |
Privacy Notice:
This document contains proprietary and confidential material
which is legally privileged. The contents of this document
may not be disclosed or distributed without the consent of
Premier Heart, LLC, or of the patient whose records are
contained herein.
|
MCG Test Results
Test ID |
Date |
ECG Quality |
Local Ischemia |
Global Ischemia |
3095297 |
2007-05-07 16:25:01 |
Good |
None |
None |
|
Disclaimer:
Clinical studies have shown that MCG has a sensitivity
of 90+% with 7±2% false negative results and a
specificity of 85+% with 15±3% false positive results
in detecting ischemia due to coronary artery disease
(CAD). A positive CAD ischemia result does not guarantee
that the subject has the disease, and a negative CAD ischemia result
does not guarantee that the subject does not have the disease.
MCG analysis has the following detection rates for
coronary arterial plaque luminal encroachment levels:
40-50% encroachment |
75% detection rate |
50-70% encroachment |
90% detection rate |
>70% encroachment |
96% detection rate |
MCG assumes that the subject has normal or corrected
serum electrolyte chemistry and complete blood count (CBC).
It also assumes that the subject has no structural anomalies
of the myocardium. If these laboratory test results are
unknown, dated, or abnormal at the time of this test, the
results may be skewed.
1Local Ischemia: regional or patchy myocardial ischemia caused by mid- or distal single or double vessel coronary artery disease (CAD).
2Global ischemia: diffuse myocardial ischemia caused by proximal large vessel (usually two vessel or more are pathological) CAD, and/or microvascular disease affecting the entire myocardium.
|
MCG Test Results
Test ID |
Date |
ECG Quality |
Local Ischemia |
Global Ischemia |
3061249 |
2007-05-03 18:10:15 |
Marginal |
None |
Very severe |
|
Disclaimer:
Clinical studies have shown that MCG has a sensitivity
of 90+% with 7±2% false negative results and a
specificity of 85+% with 15±3% false positive results
in detecting ischemia due to coronary artery disease
(CAD). A positive CAD ischemia result does not guarantee
that the subject has the disease, and a negative CAD ischemia result
does not guarantee that the subject does not have the disease.
MCG analysis has the following detection rates for
coronary arterial plaque luminal encroachment levels:
40-50% encroachment |
75% detection rate |
50-70% encroachment |
90% detection rate |
>70% encroachment |
96% detection rate |
MCG assumes that the subject has normal or corrected
serum electrolyte chemistry and complete blood count (CBC).
It also assumes that the subject has no structural anomalies
of the myocardium. If these laboratory test results are
unknown, dated, or abnormal at the time of this test, the
results may be skewed.
1Local Ischemia: regional or patchy myocardial ischemia caused by mid- or distal single or double vessel coronary artery disease (CAD).
2Global ischemia: diffuse myocardial ischemia caused by proximal large vessel (usually two vessel or more are pathological) CAD, and/or microvascular disease affecting the entire myocardium.
|
Suggestions
Disease severity:
Test | MCG Score |
3095297 |
2007-05-07 16:25:01 |
0 : none |
MCG Score Range: |
0 = x |
No disease burden |
0 < x <= 2 |
Mild disease burden |
2 < x <= 4 |
Moderate disease burden
|
4 < x <= 5.5 |
Level 1 severe (moderately severe)
|
5.5 < x <= 7.5 |
Level 2 severe (severe)
|
7.5 < x <= 15 |
Level 3 severe (very severe)
|
15 < x |
Level 4 severe (extremely severe)
|
Secondary results (pathological conditions):
Myocardial Damage Ventricular Hypertrophy Cardiomyopathy Pulmonary Heart Disease Fibrillation (likely atrial). Ventricular arrhythmia. Myocarditis or Myocardial Inflammation Rheumatic Heart Disease or remnants thereof Congenital Heart Disease or remnants thereof
Tertiary results (physiopathological conditions):
Myocardial remodeling. Decreased myocardial compliance. Likely causes include ischemia, ventricular hypertrophy, increased afterload, systemic hypertension. Increased myocardial compliance. Likely causes include ischemia, myocarditis, structural anomalies, cardiomyopathy. Decreased cardiac output reflected by decreased ejection fraction. Bradycardia Tachycardia Acute Power Failure. Likely conditions are ischemia heart disease, pump failure, supply and demand imbalance. Global asynchrony Regional or localized asynchrony
Disclaimer:
This section contains comments and suggested diagnoses or
conditions which require rigorous clinical validation.
These suggestions and comments should be considered
expert opinions and not a definitive diagnosis.
|
Suggestions
Disease severity:
Test | MCG Score |
3061249 |
2007-05-03 18:10:15 |
9 : very severe |
MCG Score Range: |
0 = x |
No disease burden |
0 < x <= 2 |
Mild disease burden |
2 < x <= 4 |
Moderate disease burden
|
4 < x <= 5.5 |
Level 1 severe (moderately severe)
|
5.5 < x <= 7.5 |
Level 2 severe (severe)
|
7.5 < x <= 15 |
Level 3 severe (very severe)
|
15 < x |
Level 4 severe (extremely severe)
|
Secondary results (pathological conditions):
Myocardial Damage Ventricular Hypertrophy Cardiomyopathy Pulmonary Heart Disease Fibrillation (likely atrial). Ventricular arrhythmia. Myocarditis or Myocardial Inflammation Rheumatic Heart Disease or remnants thereof Congenital Heart Disease or remnants thereof
Tertiary results (physiopathological conditions):
Myocardial remodeling. Decreased myocardial compliance. Likely causes include ischemia, ventricular hypertrophy, increased afterload, systemic hypertension. Increased myocardial compliance. Likely causes include ischemia, myocarditis, structural anomalies, cardiomyopathy. Decreased cardiac output reflected by decreased ejection fraction. Bradycardia Tachycardia Acute Power Failure. Likely conditions are ischemia heart disease, pump failure, supply and demand imbalance. Global asynchrony (lead II behind lead V5). Regional or localized asynchrony
Disclaimer:
This section contains comments and suggested diagnoses or
conditions which require rigorous clinical validation.
These suggestions and comments should be considered
expert opinions and not a definitive diagnosis.
|
Auto Power Spectrum of Lead V5
SIL69418 (test: 2007-05-07 16:25:01)
|
|
|
1/2 |
O |
U1 |
U2 |
U3 |
U3xy |
U4 |
N1 |
N3 |
S |
SS |
F |
FF |
A1 |
A2 |
A3 |
A4 |
A5 |
A55 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
|
|
|
Auto Power Spectrum of Lead V5
SIL30016 (test: 2007-05-03 18:10:15)
|
|
|
1/2 |
O |
U1 |
U2 |
U3 |
U3xy |
U4 |
N1 |
N3 |
S |
SS |
F |
FF |
A1 |
A2 |
A3 |
A4 |
A5 |
A55 |
- |
- |
- |
- |
- |
- |
- |
- |
+ |
+ |
- |
- |
- |
- |
- |
- |
- |
- |
- |
|
Legend
N3: Low third and/or fourth peak. Similar to N1 but historical.
S: Bradycardia; S: <60 bpm.
|
|
Auto Power Spectrum of Lead II
SIL69418 (test: 2007-05-07 16:25:01)
|
|
|
1/2 |
O |
U1 |
U2 |
U3 |
U3xy |
U4 |
N1 |
N3 |
S |
SS |
F |
FF |
A1 |
A2 |
A3 |
A4 |
A5 |
A55 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
|
|
|
Auto Power Spectrum of Lead II
SIL30016 (test: 2007-05-03 18:10:15)
|
|
|
1/2 |
O |
U1 |
U2 |
U3 |
U3xy |
U4 |
N1 |
N3 |
S |
SS |
F |
FF |
A1 |
A2 |
A3 |
A4 |
A5 |
A55 |
- |
- |
- |
- |
- |
- |
- |
+ |
+ |
+ |
- |
- |
- |
- |
- |
- |
- |
- |
- |
|
Legend
N1: Low first peak: recent damage to the mesocardium from general anesthesia, myocardial contusion, syncope, and/or dyspnea leading to hypoxia.
N3: Low third and/or fourth peak. Similar to N1 but historical.
S: Bradycardia; S: <60 bpm.
|
|
Coherence Function
SIL69418 (test: 2007-05-07 16:25:01)
|
|
|
|
|
|
Coherence Function
SIL30016 (test: 2007-05-03 18:10:15)
|
|
|
|
Notes: Decreased ejection fraction. Legend
Q1: A low first peak.
Q2: Low coherence of the transfer function.
|
|
Transfer Function
SIL69418 (test: 2007-05-07 16:25:01)
|
|
|
|
|
|
Transfer Function
SIL30016 (test: 2007-05-03 18:10:15)
|
|
|
|
|
|
Phase Angle Shift
SIL69418 (test: 2007-05-07 16:25:01)
|
|
|
P+ |
P- |
WW |
PWW+ |
PWW- |
L |
- |
- |
- |
- |
- |
- |
|
|
|
Phase Angle Shift
SIL30016 (test: 2007-05-03 18:10:15)
|
|
|
P+ |
P- |
WW |
PWW+ |
PWW- |
L |
- |
+ |
+ |
- |
- |
- |
|
Notes: Myocardial remodeling.Global asynchrony: Lead II behind Lead V5. Legend
P-: Low phase shift under the abscissa.
WW: A sharp oscillation of phase shift wave forms; usually reflects time delay between different myocardial fibers within a part of the heart due to coronary artery blockage and MI.
|
|
Impulse Response Function
SIL69418 (test: 2007-05-07 16:25:01)
|
|
|
D1 |
D2 |
f |
M1 |
M3 |
M2 |
M4 |
- |
- |
- |
- |
- |
- |
- |
|
|
|
Impulse Response Function
SIL30016 (test: 2007-05-03 18:10:15)
|
|
|
D1 |
D2 |
f |
M1 |
M3 |
M2 |
M4 |
- |
+ |
- |
- |
+ |
- |
- |
|
Notes: Myocardial remodeling.Increased myocardial compliance. Legend
D2: Trapezoid wave; current or potential arrhythmia.
M3: Three or more main peaks. Usually reflects a conduction block, atrial/ventricular dilation or increased compliance.
|
|
Cross Correlation
SIL69418 (test: 2007-05-07 16:25:01)
|
|
|
rrr |
RRR |
r |
R |
rr |
RR |
rR |
R+ |
R- |
RW+ |
RW- |
pt |
PT |
Rn |
- |
- |
+ |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
|
Legend
r: Individual difference without clinical meaning.
|
|
Cross Correlation
SIL30016 (test: 2007-05-03 18:10:15)
|
|
|
rrr |
RRR |
r |
R |
rr |
RR |
rR |
R+ |
R- |
RW+ |
RW- |
pt |
PT |
Rn |
+ |
- |
- |
- |
- |
+ |
- |
- |
- |
- |
- |
+ |
+ |
- |
|
Legend
rrr: A low main peak; low cross correlation due to ischemia or potential MI.
RR: Long R-R interval; possible current or potential arrhythmia.
pt: Neuroendocrine disturbance; pt along with 1/2, A5 or A55 suggest CAD.
PT: Neuroendocrine disturbance; PT along with 1/2, A5 or A55 suggest CAD.
|
|
Amplitude Histogram V5
SIL69418 (test: 2007-05-07 16:25:01)
|
|
|
|
Legend
V-: Low (<5mm) R waves or hypovoltage in lead V5.
Vn-: Small number of recorded events in the histogram; reflects chronic heart dysfunction for > one year.
|
|
Amplitude Histogram V5
SIL30016 (test: 2007-05-03 18:10:15)
|
|
|
|
Legend
V-: Low (<5mm) R waves or hypovoltage in lead V5.
Vn-: Small number of recorded events in the histogram; reflects chronic heart dysfunction for > one year.
|
|
Amplitude Histogram II
SIL69418 (test: 2007-05-07 16:25:01)
|
|
|
|
Legend
2-: Low (<5mm) R waves or hypovoltage in lead II.
|
|
Amplitude Histogram II
SIL30016 (test: 2007-05-03 18:10:15)
|
|
|
|
Legend
2-: Low (<5mm) R waves or hypovoltage in lead II.
2n-: Similar to but carries less impact than a postive Vn-.
|
|
ECG Trace: Test 3095297
Lead II
Lead V5
|
ECG Trace: Test 3061249
Lead II
Lead V5
|
About MCG
MCG is a new, web-based, non-invasive diagnostic tool for aiding your
physician(s) in diagnosing multiple types of heart disease, including
coronary artery disease (CAD). It adopts the principles of Systems Analysis in
mathematically analyzing the digitized resting electrocardiograph (ECG) data
from leads V5 and II simultaneously.
The results of the mathematical calculations are graphically represented as an
auto power spectrum and its variations: phase shift, impulse response,
coherence function, cross correlation and amplitude histogram. Collectively,
these mathematical transformations supply various aspects of the
electromechanical properties of the heart muscle in relationship to the
physiological properties of the blood and its impact on the myocardial
functions as a whole.
The abnormal "Ischemia Indexes" derived from each of these six functions are
integrated into a mathematical pattern which represents the myocardium as a
whole system which is used for complex pattern recognition. The computer
statistically matches each individual's transformation set to the patterns of
a large population consisting of thousands of healthy people and tens of
thousands of people with heart diseases collected from years of clinical
research, software development, and database collections. The computer
analysis is then reported to a physician who determines the final
diagnosis and therapeutic recommendations, if required.
According to our peer reviewed published (and as yet other unpublished) prospective and double blind trial data from over 1,200 patients undergoing coronary angiograms:
-
Among those who have more than 40% but less than 50% coronary artery atherosclerotic plaque lumenal encroachments in single or multiple vessels, MCG detection rates at approximately 75%
-
Among those who have more than 50% but less than 70% coronary artery atherosclerotic plaque lumenal encroachments in single or multiple vessels, MCG detection rates at approximately 90%
-
Among those who have more then 70% coronary artery atherosclerotic plaque lumenal encroachments in single or multiple vessels, MCG detection rates at approximately 96%
-
There are roughly 15(±3)% false positive cases which include:
-
Coronary artery vasospasms; Coronary Arteriopathy (connective tissue disorders, vaculitides or aneurysms)
-
Microvascular disease (peripheral vascular disease)
-
Aortic stenosis/regurgitation
-
Hypertensive heart disease and metabolic disorders
-
Renal disease, (i.e. end stage renal disease)
-
Poor quality ECG tracings
-
There are about 7(±2)% false negative cases which include:
-
Well-established coronary collateral circulations with visibly poor coronary angiogram results
-
Coronary angiogram results showed moderate lumenal encroachments, however, the MCG test was negative.
-
Poor quality ECG tracings
Finally, unlike the primary diagnosis of the presence or absence of local or
global ischemia, the secondary findings of each test (such as MI, LVH,
arrhythmias, etc) should be considered as a reference or an expert's opinions
rather than definitive diagnosis. This is due to these findings requiring
additional controlled, prospective and double blind studies for validations.
The ultimate treatment decisions are between you and your physician(s).
For more details on MCG analysis, please visit
http://www.premierheart.com/webapp/tech.php .
|
About MCG
MCG is a new, web-based, non-invasive diagnostic tool for aiding your
physician(s) in diagnosing multiple types of heart disease, including
coronary artery disease (CAD). It adopts the principles of Systems Analysis in
mathematically analyzing the digitized resting electrocardiograph (ECG) data
from leads V5 and II simultaneously.
The results of the mathematical calculations are graphically represented as an
auto power spectrum and its variations: phase shift, impulse response,
coherence function, cross correlation and amplitude histogram. Collectively,
these mathematical transformations supply various aspects of the
electromechanical properties of the heart muscle in relationship to the
physiological properties of the blood and its impact on the myocardial
functions as a whole.
The abnormal "Ischemia Indexes" derived from each of these six functions are
integrated into a mathematical pattern which represents the myocardium as a
whole system which is used for complex pattern recognition. The computer
statistically matches each individual's transformation set to the patterns of
a large population consisting of thousands of healthy people and tens of
thousands of people with heart diseases collected from years of clinical
research, software development, and database collections. The computer
analysis is then reported to a physician who determines the final
diagnosis and therapeutic recommendations, if required.
According to our peer reviewed published (and as yet other unpublished) prospective and double blind trial data from over 1,200 patients undergoing coronary angiograms:
-
Among those who have more than 40% but less than 50% coronary artery atherosclerotic plaque lumenal encroachments in single or multiple vessels, MCG detection rates at approximately 75%
-
Among those who have more than 50% but less than 70% coronary artery atherosclerotic plaque lumenal encroachments in single or multiple vessels, MCG detection rates at approximately 90%
-
Among those who have more then 70% coronary artery atherosclerotic plaque lumenal encroachments in single or multiple vessels, MCG detection rates at approximately 96%
-
There are roughly 15(±3)% false positive cases which include:
-
Coronary artery vasospasms; Coronary Arteriopathy (connective tissue disorders, vaculitides or aneurysms)
-
Microvascular disease (peripheral vascular disease)
-
Aortic stenosis/regurgitation
-
Hypertensive heart disease and metabolic disorders
-
Renal disease, (i.e. end stage renal disease)
-
Poor quality ECG tracings
-
There are about 7(±2)% false negative cases which include:
-
Well-established coronary collateral circulations with visibly poor coronary angiogram results
-
Coronary angiogram results showed moderate lumenal encroachments, however, the MCG test was negative.
-
Poor quality ECG tracings
Finally, unlike the primary diagnosis of the presence or absence of local or
global ischemia, the secondary findings of each test (such as MI, LVH,
arrhythmias, etc) should be considered as a reference or an expert's opinions
rather than definitive diagnosis. This is due to these findings requiring
additional controlled, prospective and double blind studies for validations.
The ultimate treatment decisions are between you and your physician(s).
For more details on MCG analysis, please visit
http://www.premierheart.com/webapp/tech.php .
|